Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
2.
J Clin Pathol ; 75(7): 472-476, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1203982

ABSTRACT

AIMS: The progressive increase of both the workload and the complexity of laboratory procedures, along with shortage of staff, has made evident the need to increase the efficiency in the pathology departments. To support the pathologists, a new technical professional role, the pathologists' assistant (PA), has been introduced. METHODS: We decided to carry out a retrospective analysis on PAs' performance. This was compared with that of junior/senior pathologists in the amount and type of surgical specimens examined, the number of lymph node retrieved in colorectal resections, the number of cases needing a second grossing procedure and the average time spent in grossing. As the COVID-19 pandemic period in fact resulted in a dramatic reduction of histological cases in our department, we divided PA activities into two periods, according to the COVID-19 pandemic. RESULTS: 'Simple' specimens made up the majority (92%) of the specimens examined by PAs in pre-COVID-19 period while 'complex' specimens, often neoplastic, represented the minor part (7%). However, 'simple' specimens dropped to 81% and 'complex' specimens rose to 18% in the COVID-19 period, when PAs had the chance to test themselves with more complicated surgical samples, under the supervision of a pathologist. Lymph node retrieval rate and average time spent in grossing are in line with literature data and confirm that PAs performance is comparable with pathologists' one, in selected settings. CONCLUSION: In our experience, PA has represented a fundamental time-saving resource for the pathologists, who can devote time almost exclusively to diagnostic reporting.


Subject(s)
COVID-19 , Pathology, Surgical , COVID-19/epidemiology , Delivery of Health Care , Humans , Pandemics , Pathologists , Retrospective Studies , Workforce
3.
Head Neck Pathol ; 15(4): 1409-1414, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1122819

ABSTRACT

NUT carcinoma (NUT-C) is a relatively new malignancy that was recently listed in the 4th edition of the WHO Classification of Head and Neck Tumors in 2017. NUT carcinoma is a rare, aggressive, poorly differentiated carcinoma genetically defined by chromosomal rearrangement of the nuclear protein in testis (NUTM1) gene. The prognosis is extremely poor, with a mean survival < 1 year. Recent publications suggest a multimodality treatment approach. In the existing literature, only a few reports of sinonasal NUT-C have been reported. Sinonasal NUT-C is considered a very rare entity, but because of its recent inclusion as a head and neck malignancy, its true prevalence is unknown. We report the case of a 56-year-old woman with NUT-C of the sinonasal cavities. In the case reported, the coexistence of Coronavirus disease 2019 (COVID-19)-related nasal congestion delayed the diagnosis of NUT-C. Clinical presentation, diagnosis and treatment modalities are discussed together with a review of the literature.


Subject(s)
COVID-19/complications , Delayed Diagnosis , Neoplasm Proteins/genetics , Nuclear Proteins/genetics , Paranasal Sinus Neoplasms , Squamous Cell Carcinoma of Head and Neck , Female , Humans , Middle Aged , Mutation , Pandemics , Paranasal Sinus Neoplasms/diagnosis , Paranasal Sinus Neoplasms/genetics , Paranasal Sinus Neoplasms/pathology , Paranasal Sinus Neoplasms/therapy , Prognosis , Squamous Cell Carcinoma of Head and Neck/diagnosis , Squamous Cell Carcinoma of Head and Neck/genetics , Squamous Cell Carcinoma of Head and Neck/pathology , Squamous Cell Carcinoma of Head and Neck/therapy
SELECTION OF CITATIONS
SEARCH DETAIL